3M India (523395) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
12 Feb, 2026Executive summary
Sales grew 12.7% year-over-year in Q3 FY26, with all business segments contributing to growth.
EBITDA increased 40.5% YoY in Q3 FY26, but declined 10.5% sequentially from the previous quarter.
The company recorded a net loss of Rs. 62 crores in Q3 FY26 due to exceptional items and additional tax expense.
Managing Director Ramesh Ramadurai will retire effective March 31, 2026, with Aseem Joshi appointed as successor from April 1, 2026.
Financial highlights
Q3 FY26 total income: Rs. 1,237.5 crores; nine months ended Dec 2025: Rs. 3,727.3 crores.
Q3 FY26 EBITDA: Rs. 240 crores, up 40.5% YoY; PBT before exceptional items: Rs. 189 crores.
Q3 FY26 PAT: Rs. -62 crores due to exceptional labor code impact and APA-related tax expense.
EPS for Q3 FY26: Rs. -55.09; nine months EPS: Rs. 272.50.
Nine months PAT: Rs. 307 crores; PBT (excluding special causes) for nine months: Rs. 711 crores, up 29.7% YoY.
Outlook and guidance
Management remains cautious about material cost pressures from adverse forex movements.
The company continues to monitor regulatory changes and will adjust accounting as needed.
Latest events from 3M India
- India sales up 13.6% YTD, fueled by innovation, local R&D, and strategic leadership.523395
Investor presentation11 Mar 2026 - FY 2024-25 saw 6.1% revenue growth, margin pressure, and a focus on localization and innovation.523395
Status Update13 Nov 2025 - Q2 FY26 delivered 14% sales growth and 43% PAT growth YoY, with broad-based segment gains.523395
Q2 25/263 Nov 2025 - Q1 FY25 profit rose 22% year-over-year on flat revenue, led by Consumer and Safety & Industrial.523395
Q1 24/2525 Aug 2025 - Revenue up 8% YoY, profit and margins down; Health Care leads, cost pressures persist.523395
Q3 24/2525 Aug 2025 - FY25 revenue up 6% with stable EBITDA, but net profit down 18%; Rs. 535/share dividend proposed.523395
Q4 24/2525 Aug 2025 - Sales up 7% YoY, but EBITDA and profit declined amid cost pressures; Health Care led growth.523395
Q2 24/2525 Aug 2025 - Q1 FY26 revenue up 14.3% YoY, PAT up 13.1%, and ₹535/share dividend recommended.523395
Q1 25/2625 Aug 2025